PROCEPT BioRobotics Corporation
NASDAQ:PRCTMedical - Devices
+$0.19 today
- Market cap
- $1.45B
- Beta
- 0.85
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.81
Volume 2.05M
Average 1.46M
PRCT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
PROCEPT BioRobotics CorporationNASDAQ: PRCT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $13.07M rose 29.3% year over year, behind the +41.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 20.6% from the prior quarter. Over 3 fiscal years it compounded at +66.4% a year.
Context
- Stock-based compensation amounted to 15.5% of revenue in FY2025, up 1.3 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +29.3% toward the trailing-twelve-month pace of +41.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 47.6M USD
- Year-over-year change
- +49.5%
- 4-year CAGR
- +88.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.6M | +49.5% |
| FY2024 | 2024-12-31 | 31.84M | +66.4% |
| FY2023 | 2023-12-31 | 19.13M | +85.1% |
| FY2022 | 2022-12-31 | 10.34M | +172.3% |
| FY2021 | 2021-12-31 | 3.8M | — |
Stock-Based Compensation vs competitors
How PRCT compares with its peers on the latest reported figures
- PRCT's LTM Mar 2026 stock-based compensation of $50.57M is the largest of the 5 companies compared; the peer median is $4.76M.
- Its year-over-year change of +41.7% is the highest of 4, against a peer median of +16.1%.
- Stock-based compensation amounts to 15.7% of revenue for PRCT, versus a peer median of 19.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $50.57M | +41.7% | +66.4% | 15.7% | |
| LTM Mar 2026 | $8.89M | +22.3% | — | 18.4% | |
| LTM Mar 2026 | $8.49M | +16.1% | +25.6% | 20.9% | |
| LTM Mar 2026 | $1.02M | -11.2% | -15.5% | 974.3% | |
FOCLEDAP TMS S.A. American Depositary Shares | LTM Jun 2024 | $0 | — | — | 0.0% |
| Peer median (excluding PRCT) | $4.76M | +16.1% | +5.1% | 19.6% | |
Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (59.85M) | (87.15M) | (105.9M) | (91.41M) | (95.57M) |
| Depreciation & Amortization | 3.32M | 2.84M | 3.81M | 5.23M | 6.39M |
| Deferred Income Tax | 451K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.8M | 10.34M | 19.13M | 31.84M | 47.6M |
| Change in Working Capital | (4.71M) | (11.49M) | (26.16M) | (47.33M) | (7.84M) |
| Accounts Receivables | (2.91M) | (10.81M) | (33.1M) | (35.96M) | (898K) |
| Inventory | (6.12M) | (15.25M) | (9.75M) | (17.24M) | (14.5M) |
| Accounts Payables | 812K | 3.96M | 5.79M | (2.15M) | 6.65M |
| Other Working Capital | 3.52M | 10.61M | 10.9M | 8.02M | 909K |
| Other Non-Cash Items | (345K) | 5.08M | 1.12M | 2.45M | 433K |
| Operating Cash Flow | (57.33M) | (80.38M) | (108M) | (99.21M) | (48.99M) |
| Capital Expenditures | (592K) | (2.65M) | (25.21M) | (4.41M) | (9.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (592K) | (2.65M) | (25.21M) | (4.41M) | (9.36M) |
| Debt Repayment | 0 | 1.2M | 0 | 0 | 0 |
| Common Stock Issued | 172.36M | 0 | 161.71M | 164.52M | 11.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.04M | 2.42M | 6.09M | 15.6M | 0 |
| Financing Cash Flow | 262.12M | 3.61M | 167.8M | 180.13M | 11.19M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (74K) |
| Net Change in Cash | 204.19M | (79.42M) | 34.59M | 76.5M | (47.22M) |
| Free Cash Flow | (57.93M) | (83.04M) | (133.21M) | (103.62M) | (58.34M) |
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
Intrinsic Alpha fair value
Locked
Current Price
$25.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.